24th Int'l Prostate Cancer Update Articles

VAIL, CO USA (UroToday.com) - Background: Radium-223 is a targeted alpha-emitter that selectively binds to bone metastases with high-energy, short-range (< 100 μm) alpha-particles, and is approved by the US Food and Drug Administration and European Commission for treatment of patients with CRPC, symptomatic bone metastases, and no known visceral metastatic disease.

VAIL, CO USA (UroToday.com) - Background: For men with prostate cancer requiring androgen suppression, intermittent androgen deprivation (IAD) has been proposed as an alternative to continuous androgen deprivation (CAD).

VAIL, CO USA (UroToday.com) - Objectives: Stereotactic Body Radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer.

VAIL, CO USA (UroToday.com) - Presented by Peter Hoskin, Mona Wahba, John Logue, David Bottomley, Sten Nilsson, Fang Fang, Jose Garcia-Vargas, Karin Staudacher, Paul Cislo, Jonathan Reuning-Scherer, and Christopher Parker at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by E. Francisco G. La Rosa, MD, Cliff Jones, DDS, Paul Arangua, E. David Crawford, MD, and Leander Van Neste, PhD at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by E. David Crawford, Neal Shore, Celestia Higano, Anders Neijber and Vladimir Yankov at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by Thomas P. Kole, Leonard N. Chen, Joy S. Kim, Rudy Moures, Thomas Young, Siyuan Lei, Simeng Suy, Anatoly Dritschilo, John H. Lynch, and Sean P. Collins at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA